DavidHenryAggenMDPhD

PubMed

• Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
  David H Aggen, Jonathan E Rosenberg> ;Nature Reviews. Clinical Oncology. 2024 Apr 15
• 2 citations
  Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
  Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David H Aggen, Ashley M Regazzi, Ziyu Chen, Michael Lattanzi, ...> ;Clinical Cancer Research. 2023 Nov 14
• A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
  Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J Shah, Emily Feld, David H A...> ;European Urology Oncology. 2023 Nov 7
• 4 citations
  Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
  David H Aggen, Carissa E Chu, Jonathan E Rosenberg> ;Clinical Cancer Research. 2023 Apr 14
• 5 citations
  Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
  Kelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, David H Aggen, Maria I Carlo, Neil J Shah, Martin H Voss, Darren R Feldman, Robert ...> ;European Urology. 2023 Mar 1
• 51 citations
  Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
  Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J Sha...> ;Journal of Clinical Oncology. 2022 Jul 20
• 25 citations
  Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
  Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arl...> ;Journal of Clinical Oncology. 2022 Apr 20
• 128 citations
  Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
  Aleksandar Obradovic, Nivedita Chowdhury, Scott M. Haake, Casey Ager, Vinson Wang, Lukas Vlahos, Xinzheng V. Guo, David H. Aggen, W. Kimryn Rathmell, Eric Jonasch, Joy...> ;Cell. 2021 May 27
• 64 citations
  Considerations for treatment duration in responders to immune checkpoint inhibitors.
  Thomas U. Marron, Aideen E. Ryan, Sangeetha M. Reddy, Sabina Kaczanowska, Rania H. Younis, Dipti Thakkar, Jiajia Zhang, Todd Bartkowiak, Rachel Howard, Kristin G. Ande...> ;Journal for Immunotherapy of Cancer. 2021 Mar 1
• 59 citations
  Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
  David H. Aggen, Casey Ager, Aleksandar Obradovic, Nivedita Chowdhury, Ali Ghasemzadeh, Wendy Mao, Matthew G. Chaimowitz, Zoila A. Lopez-Bujanda, Catherine S. Spina, Je...> ;Clinical Cancer Research. 2021 Jan 15
• 5 citations
  Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy
  Jessica Hawley, Samuel Pan, William D. Figg, Zoila A. Lopez-Bujanda, Jonathan D. Strope, David H. Aggen, Matthew Dallos, Emerson A. Lim, Mark N. Stein, Jianhua Hu, Cha...> ;The Prostate. 2020 Mar 1
• 29 citations
  Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer - Combination Therapy in the First Line Setting.
  David H. Aggen, Charles G. Drake, Brian I. Rini> ;Clinical Cancer Research. 2020 Jan 16
• 13 citations
  A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enza...
  Harshraj Leuva, Keith Sigel, Mengxi Zhou, Julia Wilkerson, David H. Aggen, Yeun-Hee Anna Park, Christopher B. Anderson, Ta-Chueh Melody Hsu, Erik Langhoff, Glen McWill...> ;Seminars in Oncology. 2019 Aug 1
• 124 citations
  Biomarkers for immunotherapy in bladder cancer: a moving target.
  David H. Aggen, Charles G. Drake> ;Journal for Immunotherapy of Cancer. 2017 Nov 21
• 29 citations
  Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.
  Thomas M. Schmitt, David H. Aggen, Kumiko Ishida-Tsubota, Sebastian Ochsenreither, David M. Kranz, Philip D. Greenberg> ;Nature Biotechnology. 2017 Nov 6
• 33 citations
  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control
  Jennifer D. Stone, Daniel T. Harris, Carolina M. Soto, Adam S. Chervin, David H. Aggen, Edward J. Roy, David M. Kranz> ;Cancer Immunology, Immunotherapy. 2014 Aug 1
• 52 citations
  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection
  Thomas M. Schmitt, David H. Aggen, Ingunn M. Stromnes, Michelle L. Dossett, Sarah A. Richman, David M. Kranz, Philip D. Greenberg> ;Blood. 2013 Jul 18
• 78 citations
  A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
  Jennifer D. Stone, David H. Aggen, Andrea Schietinger, Hans Schreiber, David M. Kranz> ;Oncoimmunology. 2012 Oct 17
• 41 citations
  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains
  David H. Aggen, Adam S. Chervin, Thomas M. Schmitt, Boris Engels, Jennifer D. Stone, Sarah A. Richman, Kurt H. Piepenbrink, Brian M. Baker, Philip D. Greenberg, Hans S...> ;Gene Therapy. 2012 Apr 1
• 17 citations
  T cell receptor engineering.
  Jennifer D. Stone, Adam S. Chervin, David H. Aggen, David M. Kranz> ;Methods in Enzymology. 2012 Jan 1
• 10 citations
  Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8
  Jennifer D. Stone, David H. Aggen, Adam S. Chervin, Samanthi Narayanan, Thomas M. Schmitt, Philip D. Greenberg, David M. Kranz> ;Journal of Immunology. 2011 May 1
• 33 citations
  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors
  David H. Aggen, Adam S. Chervin, Francis K. Insaidoo, Kurt H. Piepenbrink, Brian M. Baker, David M. Kranz> ;Protein Engineering, Design & Selection. 2011 Apr 1
• 45 citations
  Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments
  Sarah A. Richman, David H. Aggen, Michelle L. Dossett, David L. Donermeyer, Paul M. Allen, Philip D. Greenberg, David M. Kranz> ;Molecular Immunology. 2009 Feb 1
• 48 citations
  Engineering higher affinity T cell receptors using a T cell display system.
  Adam S. Chervin, David H. Aggen, John M. Raseman, David M. Kranz> ;Journal of Immunological Methods. 2008 Dec 31
• Join now to see all

Lectures

• Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma. 
  2019 ASCO Annual Meeting - 6/1/2019